BioSpace News Archive

Surface Oncology announced that Jeff Goater, chief executive officer, and Robert Ross, M.D., chief medical officer, will participate in a fireside chat at the 40th Annual Cowen Healthcare Conference, discussing Surface Oncology’s lead programs, SRF617 and SRF388.

Vertex Pharmaceuticals Incorporated announced that KALYDECO® will be available to eligible patients with cystic fibrosis in New Zealand from March 1.

Prescription Drug User Fee Act (PDUFA) date for rimegepant Zydis® orally dissolving tablet (ODT) set for 1Q2020 and Company prepared for commercialization

Menlo Therapeutics Inc., a late-stage biopharmaceutical company, announced it will host a conference call and webcast on Wednesday, February 26, 2020 at 8:30 am ET to discuss results from the Phase 2 trial of serlopitant in patients with chronic pruritus of unknown origin.

The U.S. Senate rejected the Born-Alive Abortion Survivors Protection Act and Pain-Capable Unborn Child Protection Act, despite the best efforts of Senate Majority Leader Mitch McConnell and other pro-life leaders.

Thermo Fisher Scientific Inc., the world leader in serving science, announced that its Board of Directors has authorized a quarterly cash dividend of $0.22 per common share, payable on April 16, 2020, to shareholders of record as of March 16, 2020.

Securecell is proud to announce the partnership with Alit Life Science, Biofors Global and Danyel Biotech to build its market presence in China, Korea and Israel as a major step to further penetrate new markets.

ProBioGen AG today announced that ImmunOs Therapeutics AG has signed a Manufacturing Services Agreement for their novel platform of multitasking biologics. ProBioGen will support ImmunOs in the development of their biologics using its recently launched DirectedLuck Transposase technology and conducting large scale GMP manufacturing.

Domainex Ltd., a fully integrated provider of drug discovery services from its Medicines Research Centre near Cambridge, UK, has entered into a research partnership with LUNAC Therapeutics Limited to discover novel anticoagulant therapies that have a reduced risk of bleeding compared to current therapies.

Reduced stress is linked to changes in the profile of plasma metabolites, a new study from the University of Eastern Finland shows. According to the researchers, the findings can shed light on the associations of psychological well-being with metabolism and the risk of disease. The study was published in Scientific Reports.